PubRank

J L Mohler

Author PubWeight™ 59.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001 4.12
2 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001 3.37
3 Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993 2.76
4 Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995 2.00
5 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998 1.92
6 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997 1.90
7 Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996 1.64
8 Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A 1989 1.55
9 Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994 1.38
10 Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996 1.23
11 The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998 1.20
12 In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997 1.16
13 HE2beta and HE2gamma, new members of an epididymis-specific family of androgen-regulated proteins in the human. Endocrinology 2000 1.07
14 Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol 1987 1.05
15 Sclerosing lipogranulomatosis: a case report of scrotal injection of automobile transmission fluid and literature review of subcutaneous injection of oils. Plast Reconstr Surg 1993 1.05
16 Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999 1.03
17 Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 2001 1.00
18 A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989 0.98
19 Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996 0.97
20 Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 1999 0.96
21 Downregulation of the beta4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol 1998 0.96
22 Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993 0.95
23 In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993 0.94
24 An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. J Cancer Res Clin Oncol 1994 0.93
25 Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 2001 0.92
26 Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 1999 0.92
27 Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J Urol 1991 0.88
28 Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues. Biochem Mol Biol Int 1994 0.86
29 Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells. J Urol 1987 0.86
30 Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994 0.86
31 Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 1999 0.85
32 Adrenal insufficiency following unilateral adrenalectomy: a case report. J Urol 1986 0.85
33 Semiautomated nuclear shape analysis of prostatic carcinoma and benign prostatic hyperplasia. Anal Quant Cytol Histol 1994 0.84
34 Patient positioning for radical retropubic prostatectomy. Urology 1998 0.84
35 Isolation and characterization of propagable cell lines (HUNC) from the androgen-sensitive Dunning R3327H rat prostatic adenocarcinoma. Carcinogenesis 1998 0.83
36 Partial adrenalectomy for renal cell carcinoma with bilateral adrenal metastases. J Urol 1995 0.83
37 Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989 0.81
38 The adrenal response to trauma, operation and cosyntropin stimulation. Surg Gynecol Obstet 1990 0.81
39 Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer. BJU Int 2004 0.80
40 Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer. Urology 1996 0.80
41 The evaluation of creatinine clearance in spinal cord injury patients. J Urol 1986 0.79
42 Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. J Urol 1992 0.79
43 The role of motility proteins and metastasis-suppressor genes in prostate cancer progression. Stem Cells 1996 0.78
44 American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer. Clin Oncol (R Coll Radiol) 2011 0.77
45 Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 1996 0.77
46 The effect of nutritional status and support on morbidity and mortality of bladder cancer patients treated by radical cystectomy. J Urol 1987 0.77
47 Prediction of metastatic potential of aspirated cells from the Dunning R-3327 prostatic adenocarcinoma model. J Urol 1992 0.77
48 Cell motility as an index of metastatic ability in prostate cancers: results with an animal model and with human cancer cells. Cancer Treat Res 1992 0.77
49 The evaluation of postoperative function of the adrenal gland. Surg Gynecol Obstet 1985 0.76
50 Preservation of sexual function in women after anterior exenteration for bladder cancer. Br J Urol 1998 0.76
51 Preoperative lymph node evaluation in prostatic cancer patients who are surgical candidates: the role of lymphangiography and computerized tomography scanning with directed fine needle aspiration. J Urol 1985 0.76
52 The serum and urinary cortisol response to operative trauma. Surg Gynecol Obstet 1985 0.76
53 Diagnosis and therapy of acute adrenal insufficiency. Pharmacotherapy 1989 0.75
54 Treatment issues in clinically localized prostatic carcinoma. J Urol 1995 0.75
55 Unusual urological presentations of acquired immune deficiency syndrome: large cell lymphoma. J Urol 1987 0.75
56 Genetic instability assessed by sister chromatid exchange analysis in the Dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential. Prostate 1995 0.75
57 The decoy catheter. J Urol 1990 0.75
58 Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J Urol 1990 0.75
59 Correlation of prognosis to nuclear roundness and to flow cytometric light scatter. Anal Quant Cytol Histol 1987 0.75
60 Methotrexate elimination in a patient with an orthotopic neobladder with and without a urethral catheter. Pharmacotherapy 1997 0.75
61 Peripheral airway function in healthy young cigarette smokers. Lung 1979 0.75
62 Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model. J Urol 1987 0.75
63 Abnormal tests don't change smoking habits. N Engl J Med 1980 0.75
64 Comparison of the digital rectal examination, endorectal ultrasound, and body coil magnetic resonance imaging in the staging of adenocarcinoma of the prostate. Urol Radiol 1991 0.75
65 Effects of alpha-adrenergic agonist on neobladder water and electrolyte transport. Urology 1994 0.75
66 Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma. Anal Quant Cytol Histol 1992 0.75
67 False positive beta-human chorionic gonadotropin in testicular cancer. Urology 1987 0.75
68 Failure of creatinine clearance to predict gentamicin half-life in a renal transplant patient with diabetes mellitus. Clin Pharm 1985 0.75
69 Isolation and partial characterization of an epithelial cell line (RPE-F344) from the regenerating prostate of a normal adult male rat. Prostate Cancer Prostatic Dis 1999 0.75
70 New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. Eur Urol 1990 0.75
71 Small airway disease: comparison of tests in young smokers versus nonsmokers. South Med J 1978 0.75